Pharmacotherapy of alcohol addiction – new reports

Grzegorz Boreński, Magdalena Wójcik, Julita Poleszak, Marta Szabat, Przemysław Szabat, Joanna Milanowska


Introduction: Alcohol use disorder is a worldwide problem. It can affect people and their families regardless of culture or age. Yet there is still no one good form of treatment. Each patient requires an individual approach. Unfortunately, for some patients current available treatments is not enough. There is a great need for new drugs that could be helpful in treating alcohol use disorder. Here, we integrate the information about the disease itself, current available treatments which is disulfiram, acamprostate and naltrexone and new possibilities in pharmacotherapy.
The aim of the study: The purpose of this systemic review was to collect and analyse current and new methods of treatment of alcohol addiction.
Material and method: Standard criteria were used to review the literature data. The search of articles in the PubMed database was carried out using the following keywords: alcohol, treatment, addiction, pharmacotherapy, psychotherapy.
Description of the state of knowledge:Currently the basis for alcoholism treatment are psychosocial and behavioral treatments and classic medicines such as disulfiram, acamprostate, naltrexone. New promising off-label medication are baclofen, gabapentin, pregabaline, topiramate, γ‐hydroxybutyrate, nalmefene, ondansetron andvarenicline. The use of these drugs may bring more benefits than use of older medicines. There are numerous studies proving the effectiveness of these drugs.
Summary: Therapy for alcohol addiction could be more effective using other medicines than currently. Further research is needed to confirm the effect of new off-label medicines.


alcohol; addiction; pharmacotherapy; treatment

Full Text:



Davis C. Home detox - supporting patients to overcome alcohol addiction. Australian prescriber. 2018 41(6):180-182.

KoobGF. Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction as a reward deficit disorder. Current topics in behavioral neurosciences. 2013 13:3-30.

Heilig M, Koob GF. A key role for corticotropin-releasing factor in alcohol dependence. Trends in neurosciences. 200730(8):399-406.

Koob GF, Kreek MJ. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. The American journal of psychiatry. 2007164(8):1149-59.

Koob GF. A role for brain stress systems in addiction. Neuron. 200859(1):11-34.

KoobGF.Neurocircuitry of alcohol addiction: synthesis from animal models.HandbClin Neurol. 2014 125:33-54

Enoch MA. The role of early life stress as a predictor for alcohol and drug dependence. Psychopharmacology. 2010214(1):17-31.

Palmisano M, Pandey SC. Epigenetic mechanisms of alcoholism and stress-related disorders. Alcohol. 2017 60:7-18.

Blomeyer D, Treutlein J, Esser G, Schmidt MH, Schumann G, Laucht M. Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use. Biol Psychiatry. 2008 Jan 15;63(2):146-51.

Pilowsky DJ, Keyes KM, Hasin DS (2009). Adverse childhood events and lifetime alcohol dependence. American journal of public health.2009 99(2):258-63.

Ducci F, Roy A, Shen PH, Yuan Q, Yuan NP, Hodgkinson CA, et al. Association of substance use disorders with childhood trauma but not African genetic heritage in an African American cohort. The American journal of psychiatry. 2009166(9):1031-40.

Koss MP, Yuan NP, Dightman D, Prince RJ, Polacca M, Sanderson B, et al. Adverse childhood exposures and alcohol dependence among seven Native American tribes.Am J Prev Med. 2003 Oct;25(3):238-44.

Moffett MC, Vicentic A, Kozel M, Plotsky P, Francis DD, Kuhar MJ. Maternal separation alters drug intake patterns in adulthood in rats. Biochemical pharmacology.2006 73(3):321-30.

Higley JD, Hasert MF, Suomi SJ, Linnoila M. Nonhuman primate model of alcohol abuse: effects of early experience, personality, and stress on alcohol consumption. Proceedings of the National Academy of Sciences of the United States of America. 199188(16):7261-5.

Huot RL, Thrivikraman KV, Meaney MJ, Plotsky PM. Development of adult ethanol preference and anxiety as a consequence of neonatal maternal separation in Long Evans rats and reversal with antidepressant treatment. Psychopharmacology. 2001 Dec;158(4):366-73.

Leclercq S, de Timary P, Delzenne NM, StärkelP. (2017). The link between inflammation, bugs, the intestine and the brain in alcohol dependence. Translational psychiatry. 20177(2):e1048.

Most D, Ferguson L, Harris RA. Molecular basis of alcoholism. Handbook of clinical neurology. 2014125:89-111.

Zakhari S. Overview: how is alcohol metabolized by the body?. Alcohol Res Health. 200629(4):245-54.

Ponomarev I, Wang S, Zhang L, Harris RA, Mayfield RD. Gene coexpression networks in human brain identify epigenetic modifications in alcohol dependence. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2012 32(5):1884-97.

Guerri C, Pascual M. Mechanisms involved in the neurotoxic, cognitive, and neurobehavioral effects of alcohol consumption during adolescence.Alcohol. 2010 Feb;44(1):15-26.

Lovinger DM, White G, Weight FF. Ethanol inhibits NMDA-activated ion current in hippocampal neurons.Science. 1989 Mar 31;243(4899):1721-4.

Lai CC, Chang MC, Lin HH. Acute tolerance to ethanol inhibition of NMDA-induced responses in rat rostral ventrolateral medulla neurons.J Biomed Sci. 2004 Jul-Aug;11(4):482-92.

Qiang M, Ticku MK. Role of AP-1 in ethanol-induced N-methyl-D-aspartate receptor 2B subunit gene up-regulation in mouse cortical neurons.JNeurochem. 2005 Dec;95(5):1332-41.

Volkow ND, Wang GJ, Maynard L, Fowler JS, Jayne B, Telang F, et al. Effects of alcohol detoxification on dopamine D2 receptors in alcoholics: a preliminary study.Psychiatry Res. 2002 Dec 30;116(3):163-72.

Rothblat DS, Rubin E, Schneider JS. Effects of chronic alcohol ingestion on the mesostriatal dopamine system in the rat.NeurosciLett. 2001 Mar 9;300(2):63-6.

Lobo IA, Harris RA. GABA(A) receptors and alcohol. Pharmacology, biochemistry, and behavior. 2008 90(1), 90-4.

Federici M, Nisticò R, Giustizieri M, Bernardi G, Mercuri, NB. Ethanol enhances GABAB‐mediated inhibitory postsynaptic transmission on rat midbrain dopaminergic neurons by facilitating GIRK currents. European Journal of Neuroscience. 2009 29:1369-1377.

LovingerDM.Serotonin's role in alcohol's effects on the brain.Alcohol Health Res World. 1997 21(2):114-20.

Fleming MF, Manwell LB, Barry KL, Adams W, Stauffacher EA. Brief physician advice for alcohol problems in older adults: a randomized community-based trial.JFamPract. 1999 May;48(5):378-84.

Leggio L, Lee, MR. Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease. The American journal of medicine. 2016 130(2):124-134.

Osterman R, Lewis D, Winhusen T. Efficacy of motivational enhancement therapy to decrease alcohol and illicit-drug use in pregnant substance users reporting baseline alcohol use. Journal of substance abuse treatment. 201777:150-155.

Carroll KM, Kiluk BD. Cognitive behavioral interventions for alcohol and drug use disorders: Through the stage model and back again. Psychol Addict Behav. 2017 31(8):847-861.

Lundahl B, Burke BL. The effectiveness and applicability of motivational interviewing: a practice-friendly review of four meta-analyses.JClin Psychol. 2009 Nov 65(11):1232-45.

Winslow BT, Onysko M, Hebert M. Medications for Alcohol Use Disorder. Am Fam Physician.2016 Mar 15;93(6):457-65.

Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. British journal of clinical pharmacology. 201477(2):315-23.

Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G. Clinical pharmacokinetics of acamprosate.ClinPharmacokinet. 1998 Nov 35(5):331-45.

Rosenthal RN, Gage A, Perhach JL, Goodman AM. Acamprosate: safety and tolerability in the treatment of alcohol dependence. J Addict Med. 2008 2:40–50.

Dahchour A, De Witte P. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate.ProgNeurobiol. 2000 Mar;60(4):343-62.

Goh ET, Morgan MY. Review article: pharmacotherapy for alcohol dependence – the why, the what and the wherefore. Aliment PharmacolTher. 2017 45:865-882.

Azrin NH, Sisson RW, Meyers R, Godley M. Alcoholism treatment by disulfiram and community reinforcement therapy.JBehavTherExp Psychiatry. 1982 Jun;13(2):105-12.

Skinner MD, Coudert M, Berlin I, Passeri E, Michel L, Aubin HJ. Effect of the threat of a disulfiram-ethanol reaction on cue reactivity in alcoholics.Drug Alcohol Depend. 2010 Dec 1;112(3):239-46.

Johnson BA. Medication treatment of different types of alcoholism. The American journal of psychiatry. 2010167(6):630-9.

Wright C, Moore RD.Disulfiram treatment of alcoholism. Am J Med.1990 Jun;88(6):647-55.

Sudakin D. Naltrexone: Not Just for Opioids Anymore. J Med Toxicol. 201512(1):71-5.

Hulse G. K. Improving clinical outcomes for naltrexone as a management of problem alcohol use. British journal of clinical pharmacology. 201276(5):632-41.

Mitchell JM, Bergren LJ, Chen KS, Rowbotham MC, Fields HL.Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol. Neurobiol Dis.2009 Jan;33(1):72-80.

de Beaurepaire R, Sinclair J, Heydtmann M, Addolorato G, Aubin HJ, Beraha EM, et al. The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. Frontiers in psychiatry. 20199:708.

Dario A, Tomei G. A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf. 200427:799–818.

Colombo G, Gessa GL. Suppressing Effect of Baclofen on Multiple Alcohol-Related Behaviors in Laboratory Animals. Frontiers in psychiatry. 20189:475.

Rolland B, Bordet R, Cottencin O. Alcohol-dependence: The current French craze for baclofen. Addiction. 2012 107:848-849.

Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-JuhlL, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, clinical and experimental research. 201034(11):1849-57.

Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double- blind randomized controlled study. Alcohol Alcohol. 2002 37:504–8.

Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II–Preliminary clinical evidence. Alcohol ClinExp Res. 200024:67–71.

Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol. 200540:147–50.

Bschor T, Henssler J, Müller M, Baethge C. Baclofen for alcohol use disorder-a systematic meta-analysis. ActaPsychiatr Scand. 2018 138:232–42.

Rolland B, Paille F, Fleury B, Cottencin O, Benyamina A, Aubin HJ. Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey. PLoS ONE. 20149:e98062.

Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert opinion on investigational drugs. 201727(1):113-124.

Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007 68:1691–1700.

Nichols TA, Robert S, Taber DJ, Cluver J. Alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility. The mental health clinician. 20199(1):1-5.

Meyerhoff DJ, Murray DE, Durazzo TC, Pennington DL. Brain GABA and Glutamate Concentrations Following Chronic Gabapentin Administration: A Convenience Sample Studied During Early Abstinence From Alcohol. Frontiers in psychiatry. 20189:78.

Martinotti G, Di Nicola M, Tedeschi D, Andreoli S, Reina D, Pomponi M, et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharm. 2010 24(9):1367–74.

Morley KC, Kranzler HR, Luquin N, Baillie A, Shanahan M, Trent R, et al. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). Trials. 201819(1):443.

Swift RM, Aston ER. Pharmacotherapy for alcohol use disorder: current and emerging therapies. Harvard review of psychiatry. 201523(2):122-33.

Gual A, He Y, Torup L, van den Brink W, Mann K, ESENSE 2 Study Group. (2013). A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. European neuropsychopharmacology. 201323(11):1432-1442.

Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. Jama. 2000284(8):963-971.

Shen WW. Anticraving therapy for alcohol use disorder: A clinical review. Neuropsychopharmacol Rep. 2018 38:105–116.

Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O'Malley SS. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology. 2011215(4):655-63.


Copyright (c) 2019 © The Author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:

Journal Language(s): English 

PBN Poland



Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2 Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase


Universal Impact Factor 1.78 for year 2012. (

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski